MYLAN-NEVIRAPINE 200 MG — DIN 02387727
NEVIRAPINE : 200 MG · MYLAN PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is MYLAN-NEVIRAPINE?
MYLAN-NEVIRAPINE 200 MG contains NEVIRAPINE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02387727, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jun-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-NEVIRAPINE used for?
Treatment of HIV-1 infection in combination with other antiretroviral agents. Not for monotherapy. Use caution in patients with higher CD4 counts due to toxicity risks.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Nevirapine cost around the world?
Nevirapine is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 18 | 19 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 5 | EUR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
| United States | acquisition | 1 | 3 | USD███.██ |
| Australia | ex-manufacturer | 2 | 2 | AUD███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
39 pack listings across 34 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Nevirapine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Nevirapine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Nevirapine, across 8 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 1 | 1 | AURO-NEVIRAPINE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP NEVIRAPINE | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-NEVIRAPINE | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-NEVIRAPINE, APO-NEVIRAPINE XR | No marketed DIN |
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 2 | 0 | VIRAMUNE, VIRAMUNE XR | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | TEVA-NEVIRAPINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text summary (refer to full section 42 for details). |
| Storage | Not explicitly detailed in the provided text summary (refer to full section 42 for details). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Nevirapine |
|---|---|
| ATC code | J05AG01 |
| AHFS class | 08:18.08.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02387727 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2387727 |
| Brand name | MYLAN-NEVIRAPINE |
| Generic / active ingredient | NEVIRAPINE : 200 MG |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AG01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AG |
| Current status | MARKETED |
| Status date | 20-Jun-2012 |
| Original market date | 2012-06-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initiate with 200 mg once daily for 14 days (lead-in period), followed by 200 mg twice daily in combination with other antiretrovirals. Strict adherence to lead-in is required to reduce rash risk.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; severe hepatic dysfunction; pre-treatment AST/ALT >5X ULN; previous permanent discontinuation due to nevirapine-induced rash or hepatitis; St. John’s wort use.
Warnings and precautions
Fatal hepatotoxicity and severe skin reactions (SJS/TEN) risk. Do not start in women with CD4 >250 or men with CD4 >400 unless benefits outweigh risks. Intensive monitoring for first 18 weeks.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-NEVIRAPINE | 200 MG | TABLET | AURO PHARMA INC | MARKETED | 02318601 |
| JAMP NEVIRAPINE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02405776 |
| APO-NEVIRAPINE | 200 MG | TABLET | APOTEX INC | APPROVED | 02396653 |
| APO-NEVIRAPINE XR | 400 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | CANCELLED POST MARKET | 02427931 |
| TEVA-NEVIRAPINE | 200 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02352893 |
| VIRAMUNE | 200 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 02238748 |
| VIRAMUNE XR | 400 MG | TABLET (EXTENDED-RELEASE) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 02367289 |
2 · Same class — other molecules in ATC J05AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Efavirenz | AURO-EFAVIRENZ · JAMP-EFAVIRENZ · MYLAN-EFAVIRENZ · SUSTIVA 100MG · +4 more | 8 | 3 | Yes |
| Nevirapine | APO-NEVIRAPINE · APO-NEVIRAPINE XR · AURO-NEVIRAPINE · JAMP NEVIRAPINE · +4 more | 8 | 3 | Yes |
| Etravirine | INTELENCE | 3 | 2 | Yes |
| Doravirine | PIFELTRO | 1 | 1 | Yes |
| Rilpivirine | EDURANT | 1 | 1 | Yes |
| Delavirdine | RESCRIPTOR | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MYLAN-NEVIRAPINE called?
The same molecule, Nevirapine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cipla Nevirapine Oral Suspension | Latin | South Africa |
| NEVIPAN | Latin | Morocco |
| Adco-Nevirapine Tablets | Latin | South Africa |
| Aspen Nevirapine Suspension | Latin | South Africa |
| Cipla Nevirapine | Latin | South Africa |
| Nevasta | Latin | South Africa |
| NEVIMUNE | Latin | Morocco |
| Nevipin | Latin | Saudi Arabia |
| Nevir | Latin | South Africa |
| Nevirapine Viatris | Latin | Australia |
| Nevivir | Latin | South Africa |
| Sonke-Nevirapine Tablets | Latin | South Africa |
| Viramune | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.